In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.
In this study, our purpose was to explore the synergistic anti-tumor effect and mechanism of paclitaxel nanoparticles (PTX-NPs) combined with radiotherapy (RT) on human cervical carcinoma (HeLa). PTX-NPs were prepared by a solid dispersion method using methoxy poly(ethylene glycol)-poly(ɛ-caprolactone) (MPEG-PCL), which combined with RT exerted a potent and high efficient effect against cervical cancer. In vivo antitumor activity of PTX-NPs combined with RT, was estimated using nude mice carrying Hela cell xenograft tumor. The results were evaluated using microfluorine-18-deoxyglucose PET/computed tomography (18F-FDG PET/CT) and immunohistochemistry. The results showed that PTX-NPs possessed a more efficient effect than PTX when combined with RT (p < 0.05). PTX-NPs in combination with RT might inhibit cell proliferation through its action on Ki-67, and decreased micro-vessel density (MVD) associated with CD31 and vascular endothelial growth factor (VEGF). These results suggested that PTX-NPs possessed a synergistic anti-tumor effect against cervical cancer when combined with RT.
a Department of Oncology and.
YanXin
Y
Yu
a Department of Oncology and.
Shan
S
Xu
a Department of Oncology and.
Hong
H
You
a Department of Oncology and.
YinJie
Y
Zhang
a Department of Oncology and.
Bo
B
Yang
a Department of Oncology and.
XiaoYang
X
Sun
a Department of Oncology and.
LingLin
L
Yang
b Department of Nuclear Medicine , the Affiliated Hospital of Southwest Medical University , Luzhou , China.
Yue
Y
Chen
a Department of Oncology and.
ShaoZhi
S
Fu
a Department of Oncology and.
JingBo
J
Wu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000737:chemistry; D049109:Cell Proliferation / Q000187:drug effects; D059248:Chemoradiotherapy; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D019788:Fluorodeoxyglucose F18; D006367:HeLa Cells; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D050997:Nanomedicine; D053758:Nanoparticles; D017239:Paclitaxel / Q000008:administration & dosage* / Q000737:chemistry; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011091:Polyesters / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals; D013678:Technology, Pharmaceutical / Q000379:methods; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D055114:X-Ray Microtomography; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D019394:Ki-67 Antigen; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011091:Polyesters; D019275:Radiopharmaceuticals; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C439611:methoxy poly(ethylene glycol-co-epsilon-caprolactone); D019788:Fluorodeoxyglucose F18; D011092:Polyethylene Glycols; D017239:Paclitaxel
Paclitaxel; cervical cancer; nanoparticle; radiotherapy; synergistic effect